Gefitinib, the active ingredient in Geficent, is a reversible inhibitor of EGFR kinase activity, preventing the autophosphorylation of tyrosine residues. This inhibition disrupts EGFR-dependent cell proliferation. Gefitinib has a higher binding affinity for EGFR exon 19 deletion and exon 21 point mutation (L858R) than for wild-type EGFR. It also inhibits IGF and PDGF-mediated signaling at clinically relevant concentrations.
Geficent is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. Detection of these mutations must be confirmed by an FDA-approved test.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Lung cancer occurs when cells in the lung grow uncontrollably, disrupting normal lung function.
Cancerous lung cells can travel through the bloodstream to other parts of the body, forming secondary tumors.
Avoid consumption of alcohol while taking Geficent 250 since it may increase the risk of liver damage.
Geficent 250 is not recommended for use in pregnant women as it may harm the baby. Consult your doctor before taking Geficent 250
Geficent 250 is not recommended for use in breastfeeding women as it is unsafe for the baby. Consult your doctor before taking Geficent 250.
If you feel weak while taking Geficent 250, consult your doctor before driving or using tools or machines.
Geficent 250 should be used with caution in patients having kidney problems. Consult your doctor before taking Geficent 250.
Geficent 250 should be used with caution in patients having liver problems. Consult your doctor before taking Geficent 250
Geficent works by decreasing the survival rate and proliferation of cancer cells in lung tissues by blocking a protein called epidermal growth factor receptor (EGFR) which is responsible for the growth and spread of cancer cells thereby controlling the growth and spread of cancer cells to other parts of the body.
Common side effects include:
Recommended Dose:
250 mg orally once daily, with or without food, until disease progression or unacceptable toxicity occurs.
Missed Dose:
If a dose is missed, do not take it within 12 hours of the next scheduled dose.
Patients with Swallowing Difficulties:
Pediatric Use:
Safety and effectiveness in children have not been established.
Renal Impairment:
No studies were conducted in patients with severe renal impairment.
Hepatic Impairment:
Use with caution, and monitor for adverse effects.
CYP3A4 Inducers:
Strong inducers (e.g., rifampicin, phenytoin) increase the metabolism of Geficent, reducing its effectiveness. The dose may be increased to 500 mg daily and reduced back to 250 mg 7 days after discontinuing the inducer.
CYP3A4 Inhibitors:
Strong inhibitors (e.g., ketoconazole) increase plasma concentrations of Geficent.
Known hypersensitivity to Gefitinib or any component of the drug.
Pregnancy:
Lactation:
Interstitial Lung Disease (ILD):
Hepatotoxicity:
Gastrointestinal Perforation:
Severe Diarrhea:
Ocular Disorders:
Bullous and Exfoliative Skin Disorders:
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.